Mitomycin C and etoposide in advanced colorectal carcinoma: A clinical and in vitro experience that focuses the problem of schedule dependence in combination therapy

Chemotherapy

Volumn 53, Issue 3, 2007, Pages 218-225

  Seminara, P ^a,c   Pastore, C ^a   Iascone, C ^a   Cicconetti, F ^a   Nigita, G ^b   Ielapi, T ^a   Franchi, F ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c Dipartimento di Medicina Clinica   (Italy)

Author keywords

Colorectal carcinoma; Drug combination; Etoposide; Mitomycin C

Indexed keywords

ETOPOSIDE; MITOMYCIN C; SULFORHODAMINE B;

ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; APOPTOSIS; ARTICLE; BIOASSAY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CELL KILLING; CHRONOPHARMACOLOGY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOMYCIN;

EID: 34147194094     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100872     Document Type: Article

References (45)

1. Colorectal Cancer Collaborative Group: Palliative chemotherapy for advanced colorectal cancer: systemic review and meta-analysis. BMJ 2000;321:531-535.
2. Perez N, Tounigand C, Mabro M, Molitor JL, Artru P, Carola E, Andre T, Louvet C, Krulik M, de Gramont A: Long-term survival in metastatic colorectal cancer treated with leucovorin and 5-fluorouracil therapy. Rev Med Intern 2004;25:124-128.
3. Xiong HQ, Ajani JA: Treatment of colorectal cancer metastasis: the role of chemotherapy. Cancer Metastasis Rev 2004;23:143-163.
4. Goldberg RM: Current approaches to firstline treatment of advanced colorectal cancer. Clin Colorectal Cancer 2004;(suppl 11):S9-S15.
5. Rothenberg ML: Current status of secondline therapy for metastatic colorectal cancer. Clin Colorectal Cancer 2004;(suppl 11):S16-S21.
6. Braun AH, Achterrath W, Wilke H, Vanhoefer U, Harstrick A, Preasser P: New systemic frontline treatment for metastatic colorectal carcinoma. Cancer 2004;100:1558-1577.
7. Feliu J, Salud A, Escudero P, Lopez-Gomez L, Pericay C, Castanon C, de Tejada MR, Rodriguez-Garcia JM, Martinez MP, Martin MS, Sanchez JJ, Baron MG: Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study. Br J Cancer 2004;90:1502-1507.
8. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL: Oral capecitabine vs. intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer 2004;90:1190-1197.
9. Folprecht G, Kohne CH: The role of new agents in the treatment of colorectal cancer. Oncology 2004;66:1-17.
10. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
11. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
12. Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
13. Tassinari D, Arcangeli V, Panzini I, Sartori S, Gianni L, Ravaioli A: Can mitomycin C represent a valid partner for 5-fluorouracil in second-line chemotherapy of colorectal cancer? Ann Oncol 2000;11:1071.
14. Bradner WT: Mitomycin C: A clinical update. Cancer Treatment Rev 2001;27:35-50.
15. Prince TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J, Cunningham D: Phase III study of mitomycin C with protracted venous or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer 2004;3:235-242.
16. Hande KR: Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998;10:1514-1521.
17. Zaniboni A, Labianca R, Pancera G, Barni S, Frontini L, Marini G, Leporini G: Oral etoposide as second-line chemotherapy for colorectal cancer: a GISCAD study. J Chemotherapy 1995;7:246-48.
18. Tomirotti M, Lombardi F, Biasioli R, Riundi R, Scanni A: Combination of mitomycin C + etoposide in advanced gastric carcinoma. Tumori 1985;71:371-373.
19. Braybrooke JP, O'Byrne KJ, Saunders MP, Propper DJ, Salisbury AJ, Boardman P, Taylor M, Ganesan TS, Talbot DC, Harris AL: A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract. Ann Oncol 1997;8:294-296.
20. Menichetti ET, Silva RR, Tummarello D, Miseria S, Torre U, Celerino R: Etoposide and mitomycin C in pretreated metastatic breast cancer. Tumori 1989;75:473-474.
21. Voog E, Merrouche Y, Trillet-Lenoir V, Lasset C, Peaud PY, Rebattu P, Negrier S: Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary. Am J Clin Oncol 2000;23:614-616.
22. Planting AS, van der Burg ME, van der Bent MJ, de Boer-Dennert M, State G, Verweij J: Phase II study of a short course of weekly high dose cisplatin combined with longterm oral etoposide in metastatic colorectal cancer. Br J Cancer 1996;73:1265-1267.
23. Posner M, Slapak CA, Browne MJ, Clark JW, Curt G, Weitberg A, Calabresi P, Cummings FJ, Wiemann M, Urba S, et al: A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma. Am J Clin Oncol 1990;13:455-458.
24. Tompkins WA, Watrach AM, Schmale JD, Schultz RM, Harris JA: Cultural and antigenic properties of newly established cell strains derived from adenocarcinomas of the human colon and rectum. J Natl Cancer Inst 1974;52:1101-1110.
25. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-1112.
26. Chou TC, Talalay P: Quantitative analysis of dose-effect relationship: the combined effect of multiple drugs or enzyme inhibitors. Adv Enzym Regul 1984;22:27-55.
27. Sobrero A, Kerr D, Glimelius B, Van Cutsem E, Milano G, Pritchard DM, Rougier P, Aapro M: New directions in the treatment of colorectal cancer: a look to the future. Eur J Cancer 2000;36:559-566.
28. Goldberg RM: Current approaches to firstline treatment of advanced colorectal cancer. Clin Colorectal Cancer 2004;4(suppl 1):S9-S15.
29. Rothenberg ML: Current status of second-line therapy for metastatic colorectal cancer. Clin Colorectal Cancer 2004;4(suppl 1):S16-S21.
30. Grothey A, Goetz MP: Oxaliplatin plus oral fluoropyrimidines in colorectal cancer. Clin Colorectal Cancer 2004;4(suppl 1):S37-S42.
31. Mita AC, Mita MM, Rowinsky EK: Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer. Clin Colorectal Cancer 2004;4:107-123.
32. Michael M, Hedley D, Oza A, Feld R, Pintilie M, Goel R, Maroun J, Jolivet J, Fields A, Lee IM, Moore MJ: The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial. Clin Colorectal Cancer 2002;2:93-101.
33. Seminara P, Franchi F, Abdolrahimzadeh S, Gozzer M, Barone C: Cancer-associated hemolytic-uremic syndrome with spontaneous resolution: a case report. Tumori 1991;77:181-184.
34. Franchi F, Barone C, Ricevuto E, Cassano A, Astone A, Pozzo C, Sofo L, Netri G, Ratto C, Coco C: 5-Fluorouracil (FU) with folinic acid (FA) and mitomycin C (MMC) in the adjuvant treatment of colorectal carcinoma. I. Evaluation of toxicity. Med Oncol Tumor Pharmacother 1991;69-73.
35. Loike JD: VP16-213 and podophyllotoxin: a study on the relationship between chemical structure and biological activity. Cancer Chemother Pharmacol 1982;7:103-111.
36. Gehan EA: The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chron Dis 1961;13:346-353.
37. Bozko P, Larsen AK, Raymond E, Skladanowski A: Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status. Acta Biochim Pol 2002;49:109-119.
38. Dubrez L, Goldwasser F, Genne P, Pommier Y, Solary E: The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 1995;9:1013-1024.
39. Kano Y, Akutsu M, Suzuki K, Mori K, Yazawa Y, Tsunoda S: Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro. Cancer Chemother Pharmacol 1999;44:381-388.
40. Meczes EL, Pearson AD, Austin CA, Tilby MJ: Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin. Br J Cancer 2002;86:485-489.
41. Bajetta E, Stani SC, De Candis D, Zaffaroni N, Zilembo N, Cortinovis D, Aglione S, Mariani L, Formisano B, Bidoli P: Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. Ann Oncol 2003;14:242-247.
42. Tanaka R, Takii Y, Shibata Y, Ariyama H, Qin B, Baba E, Kusaba H, Mitsugi K, Harada M, Nakano S: In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines. Cancer Chemother Pharmacol 2005;56:279-285.
43. Kavgaci H, Ozdemir F, Ovali E, Yavuz A, Yavuz M, Aydin F: Effect of the farnesyl transferase inhibitor L-744,832 on the colon cancer cell line DLD-1 and its combined use with radiation and 5-FU. Chemotherapy 2005;51:319-323.
44. Grivicich I, Regner A, da Rocha Aer GB, Schunemann DP, Grass LB, Alves PA, Henriques JA, Schwartsmann G: The irinotecan/5-Fluorouracil combination induces apoptpsis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells. Chemotherapy 2005;51:93-102.
45. Newell DR: How to develop a successful cancer drug-molecules to medicines or targets to treatments? Eur J Cancer 2005;41:676-682.